This site is for U.S. healthcare professionals only

Prescribing InformationPatient Site
Request a Rep
Now Approved

If your adult patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) are still stuck on pause

Grandmother and granddaughter dancing together

Actor portrayal.
MYQORZO is not indicated
for people <18 years.

Move forward with MYQORZO

Choose MYQORZO™ to deliver:

  • Rapid and sustained symptom improvement and reduction in obstruction at Weeks 12 and 241*
  • Flexibility to rapidly titrate as early as 2 weeks, with a monitoring schedule that adapts to the needs of your patients1†
  • No treatment interruptions or clinical heart failure events observed in patients with LVEF <50% in the 24-week pivotal trial1

*Efficacy and safety were studied in a 24-week randomized, double-blind, placebo-controlled Phase 3 trial of 282 patients with symptomatic oHCM. Patients were treated with MYQORZO (initiated at 5 mg orally once daily and titrated at Weeks 2, 4, and 6 if Valsalva LVOT gradient ≥30 mmHg and LVEF ≥55% in 5-mg intervals up to a maximum once-daily dose of 20 mg) or placebo and were stabilized on background therapy for >6 weeks. Primary endpoint was peak VO2 measured at Week 24. Symptoms of oHCM were assessed by change in NYHA Functional Class, and obstruction was assessed by post-Valsalva LVOT gradient at Weeks 12 and 24.1,2

†Echocardiogram performed within 2 to 8 weeks after treatment initiation or dose adjustment. Dose adjustment based on assessed LVEF and LVOT gradient or drug interaction. After a treatment interruption due to low LVEF, resume treatment no earlier than 7 days, when LVEF ≥55% and re-initiate dose titration at the starting dose of 5 mg.1

Review clinical trial results for MYQORZO

Discover the data

Explore the safety profile for MYQORZO

Review safety data

Learn more about treating your patients with MYQORZO

Starting and staying on treatment

LVEF=left ventricular ejection fraction; LVOT=left ventricular outflow tract; NYHA=New York Heart Association; oHCM=obstructive hypertrophic cardiomyopathy; VO2=oxygen consumption.

References: 1. MYQORZO (aficamten). Prescribing information. Cytokinetics; 2025. 2. Maron MS, Masri A, Nassif ME, et al. Aficamten for symptomatic obstructive hypertrophic cardiomyopathy. N Engl J Med. 2024;390(20):1849-1861. doi:10.1056/NEJMoa2401424

IMPORTANT SAFETY INFORMATION

WARNING: RISK OF HEART FAILURE

MYQORZO reduces left ventricular ejection fraction (LVEF) and can cause heart failure due to systolic dysfunction.

Echocardiogram assessments are required prior to and during treatment with MYQORZO to monitor for systolic dysfunction. Initiation of MYQORZO in patients with LVEF <55% is not recommended. Decrease the dose of MYQORZO if LVEF is <50% and ≥40%. Interrupt the dose of MYQORZO if LVEF <40% or if the patient experiences heart failure symptoms or worsening clinical status due to systolic dysfunction.

Because of the risk of heart failure due to systolic dysfunction, MYQORZO is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the MYQORZO REMS Program.

CONTRAINDICATIONS

MYQORZO is contraindicated with concomitant use of rifampin.

WARNING AND PRECAUTIONS

Heart Failure
MYQORZO reduces cardiac contractility, which can reduce LVEF and cause heart failure.

Patients who experience a serious intercurrent illness (eg, serious infection) or arrhythmia (eg, new or uncontrolled atrial fibrillation) may be at greater risk of developing systolic dysfunction and heart failure.

Assess patients’ clinical status and LVEF prior to and during treatment and adjust the MYQORZO dose accordingly. New or worsening arrhythmia, dyspnea, chest pain, fatigue, leg edema, or elevations in N-terminal pro-B-type natriuretic peptide may be signs and symptoms of heart failure.

Initiation of MYQORZO in patients with LVEF <55% is not recommended.

MYQORZO REMS Program

MYQORZO is available only through a restricted program called the MYQORZO REMS Program, because of the risk of heart failure due to systolic dysfunction.

Notable requirements of the MYQORZO REMS Program include:

  • Prescribers must be certified by enrolling in the MYQORZO REMS Program
  • Patients must enroll in the MYQORZO REMS Program and comply with ongoing monitoring requirements
  • Pharmacies must be certified by enrolling in the MYQORZO REMS Program and must only dispense to patients who are authorized to receive MYQORZO
  • Wholesalers and distributors must only distribute to certified pharmacies

Further information is available at www.MYQORZOREMS.com, or at 1-844-285-7367.

Cytochrome P450 Interactions Leading to Heart Failure or Loss of Effectiveness
MYQORZO is metabolized primarily by CYP2C9, and to a lesser extent by CYP3A, CYP2D6, and CYP2C19 enzymes. Initiation of medications that inhibit multiple P450 pathways of MYQORZO elimination (eg, fluconazole, voriconazole, or fluvoxamine) or strong CYP2C9 inhibitors, and discontinuation of moderate-to-strong CYP3A inducers may lead to increased blood concentrations of aficamten and increase the risk of heart failure due to systolic dysfunction. Conversely, initiation of medications that induce P450 pathways of MYQORZO (eg, rifampin, moderate-to-strong CYP3A inducers) may lead to decreased blood concentrations of aficamten and potential loss of effectiveness. Assess LVEF 2 to 8 weeks after initiation of such inhibitors or after discontinuation of such inducers and adjust the dose of MYQORZO accordingly.

Advise patients of the potential for drug interactions. Advise patients to inform their healthcare provider of all concomitant medications prior to and during MYQORZO treatment.

ADVERSE REACTIONS

Hypertension (8% vs 2%) was the only adverse reaction occurring in >5% of patients and more commonly on MYQORZO than on placebo in the pivotal trial.

INDICATIONS AND USAGE

MYQORZO is indicated for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms.

Please see full Prescribing Information, including Boxed WARNING.